pre-IPO PHARMA

COMPANY OVERVIEW

Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins. By changing the activity of proteins that modify messenger RNA, we aim to develop new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases.


LOCATION

  • New York, NY, USA
  • Martinsried, , Germany

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Neurodegenerative Disease
  • Oncology

  • WEBSITE

    https://www.gothamtx.com/


    CAREER WEBSITE

    https://www.gothamtx.com/careers


    SOCIAL MEDIA


    INVESTORS

    alexandria-venture-investments celgene forbion sr-one versant-ventures


    PRESS RELEASES


    Oct 29, 2019

    Gotham Therapeutics Establishes Advanced Oncology Profiling Cascade with ProQinase to Progress its Portfolio of Epitranscriptomic Drug Candidates


    Jul 17, 2019

    Gotham Therapeutics and Mercachem Announce Progress in Compound Library Development Tailored for Epitranscriptomic Drug Discovery


    May 21, 2019

    Gotham Therapeutics and ZoBio Achieve Significant Milestone in Epitranscriptomic Drug Discovery Collaboration


    Feb 14, 2019

    Gotham Therapeutics Strengthens Board of Directors and Scientific Advisory Board


    Oct 10, 2018

    Gotham Therapeutics Launches with $54 Million Series A


    For More Press Releases


    Google Analytics Alternative